GSK is a global biopharmaceutical company that discovers, develops, and delivers specialty medicines, vaccines, and general medicines to prevent and treat disease. The company focuses its research and development on four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. GSK utilizes advanced technologies, including MAPS technology for vaccine development and antibody-drug conjugates for targeted cancer treatment, to address conditions such as COPD, chronic hepatitis B, and respiratory viruses. The company serves patients globally. Its business operations include Chemical Manufacturing and Controls (CMC) and Medicine Development and Supply (MDS).

Summarised from the company's own disclosures, fiscal year ended Dec 2025

Industry Drug Manufacturers - General Homepage gsk.com
Sector Healthcare IR page gsk.com/en-gb/investors
Tags
biopharmaceuticals, vaccines, specialty medicines, respiratory diseases, immunology, oncology, hiv, infectious diseases, antibody-drug conjugates, maps technology
Press page —

Metrics

Valuation  
Market cap £ 70.306B
Market cap (USD) $ 92.742B
P/E 12.30
PEG 1.85
P/BV 4.41
P/S 2.15
P/OCF 9.08
P/FCF 11.00
Dividend yield —
Turnover / mcap —
Returns  
ROE 43.3%
ROI 20.5%
ROIC 22.0%
Profit margin 19.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 6.7%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity 92.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 32.667B 31.376B 30.328B 29.324B 34.114B 34.099B 33.754B 30.821B 30.186B 26.431B 27.387B 28.392B 28.368B
Net profit 6.289B 2.951B 5.308B 15.621B 5.096B 6.388B 5.268B 4.046B — 4.744B 5.458B 1.853B 5.669B
Free cash flow 6.393B 5.155B 5.454B 6.26B 6.78B 7.215B — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2012 FY 2011 FY 2010 FY 2009
Share price 18.95 13.56 14.47 14.54 16.14 13.88 — — — — — — —
Price performance 12m 0.4 -0.06 -0 -0.1 0.16 — — — — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (GBP) — 6.95B 7.86B 7.05B 7.39B 6.84B 7.47B
↳ YoY growth +13.1% -10.3% +4.7% -7.4% +9.3%
↳ 5y CAGR +1.5%
Borrowings, current (GBP) — 3.73B 3.6B 3.95B 2.81B 2.35B 3.01B
Borrowings, non-current (GBP) — 23.4B 20.6B 17B 15.2B 14.6B 14.7B
Cash and deposits (GBP) 4.71B 6.29B 4.27B 3.72B 2.94B 3.87B 3.4B
Intangible assets (GBP) — 29.8B 30.1B 14.3B 14.8B 15.5B 16.7B
Right-of-use assets (GBP) — 830M 740M 687M 937M 846M 726M
Net debt (borrowings + leases - cash) (GBP) — 20.9B 19.9B 17.3B 15.1B 13.1B 14.3B
Cash flow detail
Operating cash flow (GBP) 8.02B 8.44B 7.95B 7.4B 6.77B 6.55B 7.74B
Purchases of property, plant and equipment (GBP) -1.27B -1.23B -1.17B -1.14B -1.31B -1.4B -1.35B
Purchases of intangible assets (GBP) -898M -1.01B -1.76B -1.12B -1.03B -1.58B -1.64B
Dividends paid (cash effect) (GBP) -3.95B -3.98B -4B -3.47B -2.25B -2.44B -2.56B
Share buybacks (cash effect) (GBP) — — — — 0.00 0.00 -1.38B
Interest paid (cash effect) (GBP) -895M -864M -786M -848M -766M -632M -679M
Income taxes paid (cash effect) (GBP) -1.51B -1.66B -1.29B -1.31B -1.33B -1.31B -1.2B
Free cash flow (OCF - PPE - intangibles) (GBP) 5.86B 6.2B 5.02B 5.15B 4.42B 3.57B 4.76B
Income detail
Research and development expense (GBP) 4.57B 5.1B 5.28B 5.49B 6.22B 6.4B 7.53B
↳ 5y CAGR +7.0% +8.1%
Total comprehensive income (GBP) 3.7B 7.36B 4.76B 14.8B 4.99B 2.78B 6.78B
Comprehensive income to owners (GBP) 3.15B 6.75B 4.07B 14.2B 4.64B 2.41B 6.23B
Reported Mar 4, 2022 Mar 4, 2022 Mar 4, 2022 Feb 27, 2025 Mar 5, 2026 Mar 5, 2026 Mar 5, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

• Approval based on phase I/II ALKOVE-1 trial demonstrating clinically meaningful and durable responses in pretreated patients

• Next-generation ALK inhibitor designed to help address resistance, disease in the brain and tolerability challenges

• GSK’s second approval in lung cancer this year[1]

GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has granted accelerated approval to Nelkarmi (neladalkib) for the treatment of adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have previously received the following therapy in the unresectable locally advanced or metastatic setting: one prior ALK tyrosine kinase inhibitor (TKI) consisting of alectinib, or two or more prior ALK TKIs and platinum-based chemotherapy.[2]

This approval comes ahead of the original FDA target action date of 27 November 2026 and follows the FDA's Breakthrough Therapy and Orphan Drug designations.[3]

Tony Wood, Chief Scientific Officer, GSK said: “Nelkarmi is our second new medicine approved in lung cancer this year.

Director/PDMR Shareholding Bull 0 Bear 0 Routine

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares (‘ADS’)

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of notional ADS within Dr Barron’s GSK Executive Supplemental Savings Plan account following the reinvestment of dividends

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$50.4500

2,259.160

d)

Aggregated information

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2026-11-13

f)

Place of the transaction

New York Stock Exchange (XNYS)

1.

Prompts

GSK plc (ticker GSK), listed in United Kingdom.

Company History

Date Change Detail
May 17, 2022 Renamed GLAXOSMITHKLINE PLC → GSK PLC

ETFs Holding GSK plc

ETF Weight in ETF Shares Market value As of
GSKH 96.79% 13,617 $ 713.803K Jun 30, 2026
KEAT 3.64% 86,654 $ 4.27M Nov 18, 2026
IDVZ 3.16% 120,188 $ 6.213M Jul 31, 2026
DIVY 3.13% 18,704 $ 942.869K Nov 17, 2026
UDI 2.74% 2,126 $ 111.445K Jun 30, 2026
MEDX 2.71% 9,846 $ 516.127K Jun 30, 2026
GMOI 2.29% 314,596 $ 15.808M Aug 31, 2026
BDIV 2.16% 2,783 $ 143.853K Jul 31, 2026
DIVD 2.15% 11,910 $ 590K Nov 18, 2026
DTAN 2.09% 18,388 $ 453.974K Nov 17, 2026
AQEC 1.95% 214,073 $ 11.222M Jun 30, 2026
BINV 1.79% 167,254 $ 8.767M Jun 30, 2026
AIVI 1.61% 35,856 $ 942.755K Jun 30, 2026
GINX 1.60% 33,931 $ 1.705M Aug 31, 2026
FBCV 1.30% 44,514 $ 2.301M Jul 31, 2026
NBIE 1.28% 128,278 $ 3.226M Aug 31, 2026
SEIE 1.21% 525,886 $ 13.827M Jun 30, 2026
DIHP 1.07% 2,695,065 $ 70.414M Nov 12, 2026
IVSI 1.02% 3,061 $ 80.434K Jun 30, 2026
UMMA 1.01% 118,924 $ 2.989M Aug 31, 2026
MFSI 0.95% 462,726 $ 11.621M Aug 31, 2026
DWMF 0.88% 11,342 $ 298.213K Jun 30, 2026
FFLV 0.87% 2,773 $ 143.336K Jul 31, 2026
RINT 0.87% 46,212 $ 1.214M Jun 30, 2026
FENI 0.78% 1,986,771 $ 80.149M Jun 30, 2026
BRIE 0.72% 139,759 $ 3.51M Aug 31, 2026
AVIV 0.62% 255,933 $ 12.902M Nov 16, 2026
COPY 0.58% 96,253 $ 2.417M Aug 31, 2026
FFLC 0.56% 130,344 $ 6.737M Jul 31, 2026
ENHI 0.56% 4,664 $ 118.659K Nov 16, 2026
LCTD 0.53% 66,163 $ 1.683M Nov 16, 2026
QUIZ 0.52% 19,174 $ 481.532K Aug 31, 2026
AVSD 0.51% 37,932 $ 1.912M Nov 16, 2026
RCGE 0.49% 19,458 $ 480K Nov 18, 2026
TOUS 0.48% 146,731 $ 7.585M Jul 31, 2026
FLSP 0.46% 166,524 $ 4.378M Jun 30, 2026
NTSI 0.45% 85,086 $ 2.237M Jun 30, 2026
JHID 0.39% 1,593 $ 41.884K Jun 30, 2026
AVDE 0.38% 1,477,322 $ 74.472M Nov 16, 2026
DFAI 0.37% 2,669,973 $ 67.188M Nov 12, 2026
DFSI 0.34% 153,873 $ 4.014M Nov 12, 2026
RGLO 0.34% 43,156 $ 1.134M Jun 30, 2026
APIE 0.32% 73,144 $ 3.675M Aug 31, 2026
DXIV 0.31% 16,856 $ 736.273K Nov 12, 2026
TIER 0.25% 3,410 $ 88.67K Jul 31, 2026
IQSZ 0.22% 15,031 $ 390.269K Jul 31, 2026
DFIC 0.22% 1,331,680 $ 34.394M Nov 12, 2026
IALT short -0.22% -696,662 $ -17.724M Nov 16, 2026
GEW 0.20% 11,822 $ 296.908K Aug 31, 2026
DFAX 0.13% 357,543 $ 16.045M Nov 12, 2026
CORO 0.13% 839,042 $ 21.345M Nov 16, 2026
FTLS 0.11% 55,208 $ 0.00 Nov 16, 2026
RFDI 0.04% 2,295 $ 59.743K Jul 31, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
GSK Common share — US nyse 48.17 USD 2026-09-30
GSK canonical Common share — GB lse 17.36 GBP 2026-10-12